February 20, 2024CureusOpen Access

Antifungal Susceptibility Profile of Clinical and Environmental Isolates of Aspergillus Species From a Tertiary Care Center in North India

View Full Paper

Ask AI

Bookmark

Authors

MKManharpreet KaurChristian Medical College, Vellore NSNidhi SinglaGovernment Medical College and Hospital DADeepak AggarwalSoutheast Georgia Health System

Discussion

Member takes

Implication

Observational study reveals low azole and echinocandin resistance in clinical and environmental Aspergillus isolates, highlighting the need for expanded surveillance.

Key Points

Aspergillus species from clinical and environmental sources exhibit low minimum inhibitory concentration values to itraconazole and voriconazole.
Among 102 tested isolates, one clinical strain displayed a voriconazole minimum inhibitory concentration of 2 μg/ml and two were non-wild-type for amphotericin b.
Antifungal susceptibility testing following the CLSI M38-A3 protocol highlights the necessity for ongoing multicenter surveillance of emerging resistant strains.

Cite This Study

Kaur et al. (2024) studied this question.

synapsesocial.com/papers/68e786ffb6db6435876f9c0d https://doi.org/10.7759/cureus.54586

View Full Paper

Ask AI

Bookmark

Implication

Observational study reveals low azole and echinocandin resistance in clinical and environmental Aspergillus isolates, highlighting the need for expanded surveillance.

Antifungal Susceptibility Profile of Clinical and Environmental Isolates of Aspergillus Species From a Tertiary Care Center in North India

Discussion

Member takes

Implication

Key Points

Cite This Study

Antifungal Susceptibility Profile of Clinical and Environmental Isolates of Aspergillus Species From a Tertiary Care Center in North India

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider